INVIVYD, INC. (IVVD) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $29.00K; Additional Paid in Capital, Common StockUSD $1.22B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-35.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $28.00K; Additional Paid in Capital, Common StockUSD $1.20B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-37.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $28.00K; Additional Paid in Capital, Common StockUSD $1.20B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-41.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $22.00K; Additional Paid in Capital, Common StockUSD $1.04B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-41.00K.
INVIVYD, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Partners' Capital Account, Public Sale of Units Net of Offering Costs USD | Treasury Stock, Value USD | Treasury Stock, Common, Shares shares | Treasury Stock, Shares, Retired shares | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $29.00K | $1.22B | $-35.00K | $-1.04B | $181.08M | 3 month · $2.90M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $28.00K | $1.20B | $-37.00K | $-995.88M | $203.05M | 3 month · $2.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $28.00K | $1.20B | $-41.00K | $-954.48M | $241.54M | 12 month · $11.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $22.00K | $1.04B | $-41.00K | $-943.41M | $93.07M | 3 month · $3.07M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $12.00K | $975.76M | $-39.00K | $-932.94M | $42.79M | 3 month · $3.18M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $12.00K | $972.43M | $-13.00K | $-918.28M | $54.15M | 3 month · $2.83M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $12.00K | $969.53M | $-5.00K | $-901.99M | $67.54M | 12 month · $20.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $12.00K | $966.72M | $-18.00K | $-883.55M | $83.16M | 3 month · $3.14M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $12.00K | $963.45M | $-12.00K | $-822.81M | $140.64M | 3 month · $9.13M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $12.00K | $954.06M | $-12.00K | $-775.57M | $178.50M | 3 month · $5.38M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $11.00K | $909.54M | $-13.00K | $-732.07M | $177.47M | 12 month · $18.68M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $11.00K | $904.90M | $-2.00K | $-658.41M | $246.50M | 3 month · $4.26M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $11.00K | $900.55M | $-22.00K | $-618.98M | $281.56M | 3 month · $4.68M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $11.00K | $895.60M | $-115.00K | $-568.75M | $326.75M | 3 month · $5.40M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $11.00K | $889.66M | $-272.00K | $-533.43M | $355.97M | 12 month · $21.65M | (m) | $0.00 | 0.00 | 12 month · 2.62M | 0.00 |
| 2022-09-30 | $0.00 | $11.00K | $866.24M | $46.00K | $-488.85M | $377.44M | 3 month · $7.40M | 1 month · $400.00M $400.00M | $0.00 | (m) | (m) | 0.00 |
| 2022-09-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $400.00M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $11.00K | $858.59M | $0.00 | $-443.76M | $414.84M | 3 month · $6.36M | (m) | $0.00 | (m) | (m) | 992.65K |
| 2022-03-31 | $0.00 | $11.00K | $852.16M | $0.00 | $-392.77M | $459.39M | 3 month · $1.98M | (m) | $0.00 | (m) | (m) | 0.00 |
| 2021-12-31 | $0.00 | $11.00K | $850.12M | $-8.00K | $-292.11M | $558.02M | 12 month · $17.76M | (m) | $0.00 | 468.75K | (m) | 468.75K |
| 2021-09-30 | $0.00 | $5.00K | $842.27M | $3.00K | $-209.07M | $633.21M | 3 month · $5.98M | (m) | $0.00 | (m) | (m) | 0.00 |
| 2021-06-30 | $504.71M | $1.00K | $4.07M | (m) | $-148.69M | $-144.62M | 3 month · $3.34M | (m) | $0.00 | (m) | (m) | 0.00 |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $-103.36M | 3 month · $587.00K | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $1.00K | $154.00K | $0.00 | $-65.32M | $-65.25M | 7 month · $155.00K | (m) | $85.00K | (m) | (m) | 22.60M |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-48.18M | 3 month · $7.00K | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-98.00K | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |